Alexander Z. Wei

542 total citations
19 papers, 317 citations indexed

About

Alexander Z. Wei is a scholar working on Oncology, Surgery and Immunology. According to data from OpenAlex, Alexander Z. Wei has authored 19 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Surgery and 6 papers in Immunology. Recurrent topics in Alexander Z. Wei's work include Urinary and Genital Oncology Studies (7 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Ocular Oncology and Treatments (3 papers). Alexander Z. Wei is often cited by papers focused on Urinary and Genital Oncology Studies (7 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Ocular Oncology and Treatments (3 papers). Alexander Z. Wei collaborates with scholars based in United States, France and Australia. Alexander Z. Wei's co-authors include C. Varns, A McClure, Diying Shen, B.K. Dallaire, A.J. Grillo-López, Christine A. White, Richard D. Carvajal, Catherine A. Shu, Fei Ye and Matteo S. Carlino and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Frontiers in Oncology.

In The Last Decade

Alexander Z. Wei

14 papers receiving 306 citations

Peers

Countries citing papers authored by Alexander Z. Wei

Since Specialization

Citations

This map shows the geographic impact of Alexander Z. Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Z. Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Z. Wei more than expected).

Fields of papers citing papers by Alexander Z. Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Z. Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Z. Wei. The network helps show where Alexander Z. Wei may publish in the future.

Co-authorship network of co-authors of Alexander Z. Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Z. Wei. A scholar is included among the top collaborators of Alexander Z. Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Z. Wei. Alexander Z. Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2). 2025 ·Journal of Clinical Oncology ·Yohann Loriot, Arlene O. Siefker‐Radtke, Terence W. Friedlander, Andrea Necchi, Alexander Z. Wei, Srikala S. Sridhar, (unknown), Santiago Arroyo, (unknown), Jie Liu, Carly Campbell, Justin Bader, Daniel P. Petrylak	0
2	NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors. 2025 ·Journal of Clinical Oncology ·Xin Gao, Amita Patnaik, Nehal J. Lakhani, Justin Call, Matthew D. Galsky, Benjamin Garmezy, Alexander Z. Wei, Louise Carter, Thomas Powles, Arlene O. Siefker‐Radtke, Peter H. O’Donnell, Shigehisa Kitano, Daniel Castellano, (unknown), Anthony M. Joshua, Minna Balbas, Hong‐Mei Han, Amy Chang, (unknown), Gopa Iyer	2
3	A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT). 2025 ·Journal of Clinical Oncology ·Alexander Z. Wei, Basil Bakir, Andrew T. Lenis, Christopher B. Anderson, Karie Runcie, G. Joel DeCastro, (unknown), Michael M. Shen, James M. McKiernan, Mark N. Stein	0
4	QUALITY OF LIFE, DECISIONAL REGRET, AND FEAR OF RECURRENCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER MANAGED WITH SURVEILLANCE AFTER CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY 2025 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Karie Runcie, Alexander Z. Wei, Mark N. Stein, G. Joel DeCastro, Christopher B. Anderson, James M. McKiernan, Andrew T. Lenis	1
5	Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical Complete Response after Neoadjuvant Therapy: Evidence and Consideration for Active Surveillance 2025 ·Current Urology Reports ·(unknown), John R. Christin, (unknown), (unknown), Alexander Z. Wei, Karie Runcie, Mark N. Stein, G. Joel DeCastro, Christopher B. Anderson, James M. McKiernan, Andrew T. Lenis	0
6	A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas. 2025 ·Journal of Clinical Oncology ·Matteo S. Carlino, Reinhard Dummer, Tanja Gromke, Jessica C. Hassel, Ellen Kapiteijn, Damien Kee, Sophie Piperno‐Neumann, Egle Ramelyte, Alexander N. Shoushtari, Ryan J. Sullivan, Alexander Z. Wei, (unknown), (unknown), Pedro Milanez‐Almeida, Thiruvamoor Ramkumar, A. Reynolds, (unknown), Padmaja Yerramilli-Rao, Emiliano Calvo	1
7	A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2). 2025 ·Journal of Clinical Oncology ·Yohann Loriot, Arlene O. Siefker‐Radtke, Terence W. Friedlander, Andrea Necchi, Alexander Z. Wei, Srikala S. Sridhar, (unknown), Santiago Arroyo, (unknown), Jie Liu, Carly Campbell, Justin Bader, Daniel P. Petrylak	0
8	A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2. 2024 ·Journal of Clinical Oncology ·Yohann Loriot, Arlene O. Siefker‐Radtke, Terence W. Friedlander, Andrea Necchi, Alexander Z. Wei, Srikala S. Sridhar, (unknown), Santiago Arroyo, (unknown), Jie Liu, Carly Campbell, Justin Bader, Daniel P. Petrylak	2
9	Long-Term Oncologic Outcomes in Patients With Muscle Invasive Bladder Cancer Misclassified as Achieving a Complete Clinical Response to Neoadjuvant Chemotherapy 2024 ·JU Open Plus ·Rainjade Chung, (unknown), (unknown), Helena Vila-Reyes, (unknown), G. Joel DeCastro, Christopher B. Anderson, Alexander Z. Wei, Charles G. Drake, James M. McKiernan, Andrew T. Lenis	1
10	Nonadherence to medications for chronic conditions and risk of nonadherence to androgen receptor signaling inhibitors (ARSIs) in patients with prostate cancer. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Alexander Z. Wei, Boris Gershman, Mark N. Stein, Dawn L. Hershman	0
11	Neoadjuvant immunotherapy in resectable non-small-cell lung cancer 2023 ·Therapeutic Advances in Medical Oncology ·(unknown), Alexander Z. Wei, Catherine A. Shu	14
12	Clinical and genomic correlates of imatinib response in melanomas with KIT alterations 2022 ·British Journal of Cancer ·(unknown), (unknown), Alexander Z. Wei, Fei Ye, (unknown), Matteo S. Carlino, Ryan J. Sullivan, Richard D. Carvajal, Alexander N. Shoushtari, Douglas B. Johnson	15
13	Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases 2022 ·Frontiers in Oncology ·Alexander Z. Wei, (unknown), (unknown), Michael P. Manos, (unknown), (unknown), (unknown), (unknown), (unknown), Jasmine H. Francis, Shaheer Khan, (unknown), (unknown), Takami Sato, Brian P. Marr, Rizwan Haq, Marlana Orloff, Alexander N. Shoushtari, Richard D. Carvajal	6
14	New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma 2022 ·Cancer Gene Therapy ·Alexander Z. Wei, (unknown), Richard D. Carvajal	14
15	Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA 2022 ·Seminars in Oncology ·(unknown), Alexander Z. Wei, Laurent Dercle, Harold Bien, Tito Fojo, Susan E. Bates, Lawrence H. Schwartz	2
16	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors 2022 ·Expert Opinion on Biological Therapy ·(unknown), Alexander Z. Wei, (unknown), Richard D. Carvajal	8
17	Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far 2021 ·Seminars in Oncology ·Winston Wong, (unknown), Alexander Z. Wei, Yun Kyoung Ryu, John A. Chabot, Gulam A. Manji	8
18	Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma 2001 ·Current Pharmaceutical Biotechnology ·A.J. Grillo-López, B.K. Dallaire, A McClure, (unknown), C. Varns, Alexander Z. Wei, (unknown), (unknown), Diying Shen, (unknown), Pratik S. Multani, (unknown)	17
19	Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. 1999 ·PubMed ·A.J. Grillo-López, Christine A. White, C. Varns, Diying Shen, Alexander Z. Wei, A McClure, B.K. Dallaire	226

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact